Verifying Cost Effective Conventional PCR as an Alternative to NGS in Detecting FLT3-ITD in AML at Diagnostic Time Point – A Cross Sectional Study From a Tertiary Care Centre in North India
DOI:
https://doi.org/10.21276/apalm.3871Keywords:
AML, concordance, FLT3-ITD, NPM1, recurrent genetic abnormality, sequencingAbstract
Background: Nucleophosmin1 (NPM1) and FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) are two important mutations for risk stratification in acute myeloid leukemia (AML). Newer molecular techniques, like targeted next-generation sequencing (NGS) have better sensitivity and ability to detect multiple mutations in a single run. However, their application is limited in resource-constrained set-ups. We aimed to compare the analytical performance of conventional PCR with NGS for detection of FLT3-ITD mutations at diagnosis and to analyze the prevalence of NPM1 and FLT3-ITD mutations in AML in this region.
Methods: Conventional PCR and real-time PCR were performed in 130 AMLs to detect FLT3-ITD and NPM1 mutations (A, B or D mutations) respectively. Sanger sequencing was performed in 21 NPM1 mutated samples for sub-typing. Targeted NGS (Ion Torrent platform) was performed in 20 random paired samples to detect FLT3-ITD mutation for comparison of analytic performance between these techniques.
Result: Concordance between conventional PCR and targeted NGS was high (95%) with a good agreement (kappa ratio=0.8). Fourteen (10.8%) cases had both the mutations, 12 (9.2%) and 27 (20.8%) cases had NPM1 mutation and FLT3-ITD mutation respectively. NPM1 mutant type A was detected in 90.5% (19/21) and type D in 9.5% (2/21) patients.
Conclusion: Conventional PCR was compared well with targeted NGS (Ion Torrent platform) in detecting FLT3-ITD mutation. This finding supports a complementary role for PCR alongside NGS for FLT3-ITD detection in diagnostic samples specially in LMIC. Compared to published data, frequency of isolated NPM1 mutation was lower while that of FLT3-ITD mutation was higher in our AML cohort.
References
1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. doi:10.1182/blood.2022016867
2. Pakakasama S, Kajanachumpol S, Kanjanapongkul S, Sirachainan N, Meekaewkunchorn A, Ningsanond V, et al. Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia. Int J Lab Hematol. 2008;30:286–91. doi:10.1111/j.1751-553X.2007.00954.x
3. Cree IA. The WHO Classification of Haematolymphoid Tumours. Leukemia. 2022;36:1701–2. doi:10.1038/s41375-022-01625-x
4. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. doi:10.1182/blood-2016-08-733196
5. Bubán T, Koczok K, Földesi R, Szabó G, Sümegi A, Tanyi M, et al. Detection of internal tandem duplications in the FLT3 gene by different electrophoretic methods. Clin Chem Lab Med. 2012;50:301–10. doi:10.1515/CCLM.2011.762
6. Spencer DH, Abel HJ, Lockwood CM, Payton JE, Szankasi P, Kelley TW, et al. Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next-Generation Sequencing Data. J Mol Diagn. 2013;15:81–93. doi:10.1016/j.jmoldx.2012.08.001
7. Blätte TJ, Schmalbrock LK, Skambraks S, Lux S, Cocciardi S, Dolnik A, et al. getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. 2019;33:2535–9. doi:10.1038/s41375-019-0483-z
8. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99:3. doi:10.3324/haematol.2013.093765
9. Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, et al. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn. 2017;19:43–56. doi:10.1016/j.jmoldx.2016.07.012
10. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–35. doi:10.1182/blood.v99.12.4326
11. Ayachi OS. Prevalence and Effect Evaluation of FLT3 and NPM1 Mutations in Acute Myeloid Leukemia Patients in Eastern Algeria. Int J Hematol Oncol. 2018;28:169–79. doi:10.4999/uhod.182822
12. Niparuck P, Limsuwanachot N, Pukiat S, Chantrathammachart P, Rerkamnuaychoke B, Magmuang S, et al. Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. Exp Hematol Oncol. 2019;8:3. doi:10.1186/s40164-019-0127-z
13. Mahmood R, Altaf C, Malik HS, Khan SA. Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia. Pak J Med Sci. 2019;35:23–8. doi:10.12669/pjms.35.1.285
14. Mat Yusoff Y, Abu Seman Z, Othman N, Kamaluddin NR, Esa E, Zulkiply NA, et al. Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia. Asian Pac J Cancer Prev. 2019;20:1749–55. doi:10.31557/APJCP.2019.20.6.1749
15. Piras G, Uras A, Cucca A, Monne M, Costa A, Chiriu S, et al. Acute Myeloid Leukemia (AML) Risk Stratification Using the European Leukemianet 2022 Classification in a Real-Life Cohort of Patients from Sardinia, Italy. Blood. 2022;140:9156–7. doi:10.1182/blood-2022-163249
16. Sazawal S, Singh N, Jain S, Chhikara S, Chaubey R, Bhattacharyya J, et al. NPM1 and FLT3 mutations in acute myeloid leukemia with normal karyotype: Indian perspective. Indian J Pathol Microbiol. 2017;60:355. doi:10.4103/IJPM.IJPM_501_15
17. Marshall RC, Tlagadi A, Bronze M, Kana V, Naidoo S, Wiggill TM, et al. Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort. Int J Lab Hematol. 2014;36:656–64. doi:10.1111/ijlh.12204
18. Bhattacharyya J, Nath S, Saikia KK, Saxena R, Sazawal S, Barman MP, et al. Prevalence and Clinical Significance of FLT3 and NPM1 Mutations in Acute Myeloid Leukaemia Patients of Assam, India. Indian J Hematol Blood Transfus. 2018;34:32–42. doi:10.1007/s12288-017-0821-0
19. Selim D, Alonzo TA, Othus M, Gerbing R, Ostronoff F, Tarlock K, et al. Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration. Blood. 2016;128:285–285. doi:10.1182/blood.V128.22.285.285
20. Boonthimat C, Thongnoppakhun W, Auewarakul CU. Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica. 2008;93:10. doi:10.3324/haematol.12937
21. Ahmad F, Mandava S, Das BR. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol. 2009;27:90–7. doi:10.1002/hon.883
22. Rothenberg-Thurley M, Herold T, Görlich D, Sauerland C, Janke H, Prassek VV, et al. NPM1 Variant Allele Frequency and Outcomes in AML. Blood. 2018;132:1486–1486. doi:10.1182/blood-2018-99-112549
23. Ghosh K, Swaminathan S, Madkaikar M, Gupta M, Kerketta L, Vundinti B. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India. Ann Hematol. 2012;91:1703–12. doi:10.1007/s00277-012-1509-z
24. Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica. 2016;101:e55–8. doi:10.3324/haematol.2015.133819
25. Wang L, Xu W lai, Meng H tao, Qian W bin, Mai W yuan, Tong H yan, et al. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics. J Zhejiang Univ Sci B. 2010;11:762–70. doi:10.1631/jzus.B1000052
26. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011–20. doi:10.1182/blood-2005-08-3167
27. Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2016;31:11–7. doi:10.1038/leu.2016.163
28. Naseem S, Binota J, Varma N, Virk H, Varma S, Malhotra P. NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia. Int J Hematol-Oncol Stem Cell Res. 2021;15:15–26. doi:10.18502/ijhoscr.v15i1.5246
29. Deka RR, Naseem S, Bhatia P, Binota J, Sonam P, Rana P, et al. FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre. Clin Lymphoma Myeloma Leuk. 2022;22:416–23. doi:10.1016/j.clml.2021.12.007
30. Rastogi P, Naseem S, Varma N, Varma S. Nucleophosmin mutation in de-novo acute myeloid leukemia: NPM1 mutation in AML. Asia Pac J Clin Oncol. 2016;12:77–85. doi:10.1111/ajco.12442
31. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9. doi:10.1182/blood.V98.6.1752
32. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–80. doi:10.1182/blood-2002-05-1440
33. Chauhan PS, Ihsan R, Singh LC, Gupta DK, Mittal V, Kapur S. Mutation of NPM1 and FLT3 Genes in Acute Myeloid Leukemia and Their Association with Clinical and Immunophenotypic Features. Dis Markers. 2013;35:581–8. doi:10.1155/2013/582569
34. Gajendra S, Gupta R, Thakral D, Gupta SK, Jain G, Bakhshi S, et al. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations. Int J Lab Hematol. 2023;45:221–8. doi:10.1111/ijlh.14007
35. Verhaak RGW, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747–54. doi:10.1182/blood-2005-05-2168
Downloads
Additional Files
Published
Issue
Section
License
Copyright (c) 2026 Riju Rani Deka, Neelam Varma, Shano Naseem, Prateek Bhatia, Pankaj Malhotra, Bipul Kumar Das
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
